Precious metals and health plan buying:
Clostridrium difficile (aka C. diff) is an intestinal pathogen that is hard to treat (recurrence is frequent) and strongly associated with contact with health facilities and treatment with antibiotics. It is a classic scenario – an elderly person comes into hospital for a pneumonia, is treated with broad spectrum antibiotics which disrupt the gut flora allowing C. diff to take hold. This is followed by multiple rounds of treatment and relapse, with rapid functional decline… leading to death. In this extensive surveillance study the authors rigorously quantify the enormous burden of disease from C. diff in terms of mortality and morbidity in the United States, double that of previous estimates, with nearly half a million cases and 30,000 deaths yearly. It is fortunate that the new approach of fecal transplants is highly promising and offers new solutions.
Burden of Clostridium difficile Infection in the United States; Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
The New England Journal of Medicine is a premier medical journal covering many issues of interest to the health sector. In this monthly series we offer a brief overview of highlights that might be of interest to our clients and others.